NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study ...
Cemsidomide demonstrated a 50% ORR at 100 μg, with one patient achieving a complete response and no detectable disease. The phase 1 study's dose-escalation phase is complete, and the 100 μg dose is ...
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback